Clinical Trials /

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

NCT03072238

Description:

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Related Conditions:
  • Prostate Adenocarcinoma
Recruiting Status:

Active, not recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
  • Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Clinical Trial IDs

  • ORG STUDY ID: CO39303
  • NCT ID: NCT03072238

Conditions

  • Metastatic Prostate Cancer

Interventions

DrugSynonymsArms
IpatasertibIpatasertib + Abiraterone
AbirateroneIpatasertib + Abiraterone
PlaceboPlacebo + Abiraterone

Purpose

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Trial Arms

NameTypeDescriptionInterventions
Ipatasertib + AbirateroneExperimentalIpatasertib and abiraterone, administered orally, in 28-day cycles
  • Ipatasertib
  • Abiraterone
Placebo + AbirateroneActive ComparatorPlacebo plus abiraterone, administered orally, in 28-day cycles
  • Abiraterone
  • Placebo

Eligibility Criteria

        Inclusion Criteria:

          -  Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening

          -  Adequate hematologic and organ function within 28 days before the first study
             treatment

          -  Ability to comply with the study protocol, in the investigator's judgment

          -  Willingness and ability of participants to use the electronic device to report
             selected study outcomes; Caregivers and site staff can assist with patient diary input
             but patient must be able to independently comprehend and answer the questionnaires

          -  Life expectancy of at least 6 months

          -  Agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm

          -  For enrollment into the China extension cohort, residence in the People's Republic of
             China

        Disease-specific Inclusion Criteria:

          -  Histologically confirmed prostate adenocarcinoma without neuroendocrine
             differentiation or small-cell features

          -  Consent to provide a formalin-fixed paraffin-embedded (FFPE) tissue block (preferred)
             or a minimum of 15 (20 preferred) freshly cut unstained tumor slides from the most
             recently collected, available tumor tissue accompanied by an associated pathology
             report (with tumor content information, Gleason score, and disease staging) for PTEN
             IHC and NGS testing and for other protocol-mandated secondary and exploratory
             assessments. If only 12-14 slides are available, the patient may still be eligible for
             the study, after discussion with and approval by the Medical Monitor. Cytologic or
             fine-needle aspiration samples are not acceptable. Tumor tissue from bone metastases
             is not acceptable

          -  A valid PTEN IHC result (testingcentral laboratory tested with results directly sent
             to IxRS) (e.g., participants with an "invalid" or "failed" PTEN IHC result are not
             permitted to enroll)

          -  Metastatic disease documented prior to randomization by clear evidence of bone lesions
             on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or
             magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1

          -  Asymptomatic or mildly symptomatic form of prostate cancer

          -  Progressive disease before initiating study treatment

          -  Ongoing androgen deprivation with gonadotropin-releasing hormone (GnRH) analog or
             bilateral orchiectomy, with serum testosterone <= 50 ng/dL (<= 1.7 nmol/L) within 28
             days before randomization

        Exclusion Criteria:

          -  Inability or unwillingness to swallow whole pills

          -  History of malabsorption syndrome or other condition that would interfere with enteral
             absorption

          -  Clinically significant history of liver disease consistent with Child-Pugh Class B or
             C, including cirrhosis, current alcohol abuse, or current known active infection with
             hepatitis B virus (HBV) or hepatitis C virus (HCV)

          -  Need of more than 10 mg/day of prednisone or an equivalent dose of other
             anti-inflammatory corticosteroids as a current systemic corticosteroid therapy to
             treat a chronic disease (e.g., rheumatic disorder)

          -  Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1,
             Cycle 1

          -  Immunocompromised status because of current known active infection with HIV or because
             of the use of immunosuppressive therapies for other conditions

          -  Major surgical procedure or significant traumatic injury within 28 days prior to Day
             1, Cycle 1, or anticipation of the need for major surgery during study treatment

          -  History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such
             as structural heart disease (e.g., severe left ventricular systolic dysfunction, left
             ventricular hypertrophy), untreated coronary heart disease (symptomatic or with
             ischemia demonstrated by diagnostic testing), myocardial infarction or atrial
             thrombotic events within the past 6 months, severe unstable angina, New York Heart
             Association Class III and IV heart disease or depressed left ventricular ejection
             fraction (LVEF; previously documented LVEF < 50% without documentation of recovery),
             clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia,
             hypocalcemia), or family history of sudden unexplained death or long QT syndrome

          -  History of another malignancy within 5 years prior to randomization, except for either
             adequately treated non-melanomatous carcinoma of the skin, adequately treated melanoma
             in situ, adequately treated non-muscle-invasive urothelial carcinoma of the bladder
             (Tis, Ta, and low grade T1 tumors), or other malignancies where the patient has
             undergone potentially curative therapy with no evidence of disease and are deemed by
             the treating physician to have a recurrence rate of <5% at 5 years

          -  Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical
             examination finding, or clinical laboratory finding giving reasonable suspicion of a
             disease or condition that contraindicates the use of an investigational drug or that
             may affect the interpretation of the results or renders the participants at high risk
             from treatment complications.

        Disease-Specific Exclusion Criteria:

          -  Pathologic findings consistent with small-cell or neuroendocrine carcinoma of the
             prostate

          -  Any therapy including chemotherapy (e.g., docetaxel) or biological therapy (e.g.,
             vaccine, immunotherapy) for the treatment of castration-resistant prostate cancer.
             Previous treatment with flutamide, steroidal anti-androgens, androgens, estrogens,
             bicalutamide, nilutamide, or 5-α reductase inhibitor is permitted.

          -  Use of opioid medications for cancer-related pain, including codeine and
             dextropropoxyphene, currently or any time within 4 weeks of Day 1, Cycle 1

          -  Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g.,
             ketoconazole, orteronel) or investigational agents that block androgen synthesis.
             Previous treatment with itraconazole and fluconazole is permitted.

          -  Prior treatment with enzalutamide or other potent androgen-receptor blockers, approved
             or experimental (e.g., ARN-509, ODM-201, or galeterone)

          -  Prior treatment with flutamide (Eulexin®), steroidal anti-androgens (e.g., cyproterone
             acetate, chlormadinone acetate), androgens, or estrogens treatment within 4 weeks of
             Cycle 1, Day 1

          -  Prior treatment with bicalutamide (Casodex®) or nilutamide (Nilandron®) within 6 weeks
             of Cycle 1, Day 1

          -  Prior treatment with 5-alpha reductase inhibitors within 4 weeks of Cycle 1, Day 1

          -  Prior treatment with systemic radiopharmaceuticals (e.g., radium-223 and
             strontium-89). Radiopharmaceuticals for the purpose of imaging are permitted. Focal
             palliative radiation to treat cancer-related pain is permitted provided that the last
             treatment with radiation is at least 14 days prior to Cycle 1, Day 1.

          -  Prior treatment with approved or experimental therapeutic agents with known inhibition
             of the PI3K pathway, including PI3K inhibitors, AKT inhibitors, and mTOR inhibitors

          -  Administration of an investigational therapeutic agent within 28 days of Cycle 1, Day
             1

          -  Known untreated or active central nervous system (CNS) metastases (progressing or
             requiring anticonvulsant medications or corticosteroids for symptomatic control); a CT
             or MRI scan of the brain will be performed at screening if required by the local
             health authority

          -  Any chronic therapy or use of food supplements that are strong CYP3A4/5 inducers or
             inhibitors or sensitive substrates of CYP3A or CYP2D6 with a narrow therapeutic window

        Abiraterone-Specific Exclusion Criteria:

          -  Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood
             pressure ≥ 95 mmHg)

          -  History of pituitary or adrenal dysfunction

          -  Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical
             therapy

        Ipatasertib-Specific Exclusion Criteria:

          -  Type 1 or Type 2 diabetes mellitus requiring insulin at study entry

          -  History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis),
             active bowel inflammation (e.g., diverticulitis)
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:Male
Healthy Volunteers:No

Primary Outcome Measures

Measure:Investigator-Assessed Radiographic Progression-Free Survival (rPFS)
Time Frame:Up to approximately 31 months
Safety Issue:
Description:Radiographic progression-free survival is defined as time from date of randomization to the first occurrence of documented disease progression, as assessed by the investigator with use of the Prostate Cancer Working Group 3 (PCWG3) criteria or death from any cause, whichever occurs first. Disease progression for soft tissue is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; and an absolute increase of at least 5 mm in the sum of diameters of target lesions; and the appearance of one or more new lesions. Disease progression for bone lesions is defined as two or more lesions compared to baseline. rPFS will be analyzed in participants with phosphatase and tensin homolog (PTEN)-loss tumors (using the Ventana PTEN immunohistochemistry (IHC) assay) and evaluated against the intent-to-treat (ITT) population.

Secondary Outcome Measures

Measure:Time to Pain Progression
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Pain severity progression refers to pain onset for participants who are asymptomatic at baseline or pain worsening for those who are mildly symptomatic at baseline. Pain severity will be graded on a 10-point scale, with 0=no pain and 10=severe pain. Pain severity progression is defined as a ≥ 2-point absolute increase from baseline.
Measure:Time to Initiation of Cytotoxic Chemotherapy
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Time to initiation of cytotoxic chemotherapy is defined as the time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy (use of antineoplastic agents: docetaxel, cabazitaxel, mitoxantrone, estramustine, cisplatin, carboplatin, cyclophosphamide, doxorubicin, mitomycin, irinotecan, 5-fluorouracil, gemcitabine, or etoposide) for prostate cancer.
Measure:Overall Survival
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Overall Survival (OS) will be measured from randomization to the time of death due to any cause.
Measure:Time to Function Deterioration
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Time to function deterioration is defined as the time interval from the date of randomization to the date of a decrease of 10-point or more on either the 0−100 physical function (PF) or the role functioning (RF) scores from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).
Measure:Time to Prostate-Specific Antigen (PSA) Progression
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Time to PSA progression is defined as the time from the date of randomization to the first occurrence of PSA progression, per the PCWG3 criteria. PSA progression is defined as ≥ 25% relative increase of ≥ 2 ng/mL above the baseline or the smallest sum on study, which is confirmed by a second consecutive value ≥ 3 weeks later.
Measure:Time to First Opioid Use
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Time to first opioid use is defined as the time interval from the date of randomization to the date of an initiation of opioid analgesic use for cancer-related pain, and consumption reported on at least 7 consecutive days.
Measure:Time to Symptomatic Skeletal Event (SSE)
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Time to first SSE is defined as the time interval from the date of randomization to the date of an SSE.
Measure:Objective Response Rate (ORR)
Time Frame:Up to approximately 7 years
Safety Issue:
Description:An objective response is defined per response evaluation criteria in solid tumors (RECIST) v1.1 and PCWG3 criteria. Participants without a post-baseline tumor assessment will be considered non-responders. ORR is defined as complete response (CR) or partial response (PR). Complete response (CR) is defined as disappearance of all target lesions. Partial response (PR) is defined as least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Measure:PSA Response Rate
Time Frame:Up to approximately 7 years
Safety Issue:
Description:PSA response rate is defined as the percentage of participants achieving a PSA decline ≥50% from baseline. Participants without a post-baseline PSA assessment will be considered non-responders.
Measure:Investigator-Assessed rPFS in Participants With PTEN-Loss Tumors by Next-Generation Sequencing (NGS)
Time Frame:Up to approximately 7 years
Safety Issue:
Description:Investigator-assessed rPFS (time from date of randomization to the first occurrence of documented disease progression) per PCWG3 criteria will be analyzed in participants with PTEN-loss tumors by NGS. Disease progression for soft tissue is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; and an absolute increase of at least 5 mm in the sum of diameters of target lesions; and the appearance of one or more new lesions. Disease progression for bone lesions is defined as two or more lesions compared to baseline.
Measure:Plasma concentration of ipatasertib
Time Frame:1-3 hours post-dose in Cycle 1, Day 1 and Day 15, Cycle 3 Day 1 and Cycle 6 Day 1
Safety Issue:
Description:Plasma samples for pharmacokinetic characterization was collected at various timepoints in all participants.
Measure:Plasma concentration of abiraterone
Time Frame:1-3 hours post-dose in Cycle 1, Day 1 and Day 15, Cycle 3 Day 1 and Cycle 6 Day 1
Safety Issue:
Description:Plasma samples for pharmacokinetic characterization was collected at various timepoints in all participants.

Details

Phase:Phase 3
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Hoffmann-La Roche

Trial Keywords

  • Metastatic Castrate-Resistant Prostate Cancer

Last Updated